case study icon

Case Study: Radioisotope supply challenges affecting prostate cancer treatment

Jan. 30, 2023 – Health Imaging reports on a new case study published indicating that radioisotope supply issues are delaying prostate cancer treatments using 177Lu-PSMA-617, commonly known as Pluvicto.

The health care news source writes:

Following its [2022 FDA] approval, clinicians at the Dana Farber Cancer Institute report that 146 patients were referred to them to undergo therapy using 177Lu-PSMA-617 between May and October of 2022.


Of those patients, 127 were approved for the therapy, and by the end of October 2022, less than half (41%) of the approved patients had completed one cycle of 177Lu-PSMA-617.


…During the institute’s implementation, patients’ treatments were delayed by three months due to low supply of 177Lu-PSMA-617 and some (5%) patients even died while awaiting treatment.

The clinical implementation case study is published in the Journal of Nuclear MedicineClinical Implementation of 177Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges.

Learn more

Related articles

Nusano Appoints Industry Expert Alexandre Gibim as Chief Operations Officer

Nusano Appoints Industry Expert Alexandre Gibim as Chief Operations Officer

Nusano, Inc. has appointed pharmaceutical executive Alexandre Gibim as the company’s Chief Operations Officer (COO). Gibim will be responsible for enabling and scaling Nusano’s business functions to create a reliable domestic and global supply of medical radioisotopes, the active pharmaceutical ingredients (APIs) at the core of next-generation cancer therapeutics.

read more


Sign up to receive company news and updates